GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Lymphoma, Follicular
Insel Gruppe AG, University Hospital Bernprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Lymphoma, Follicular cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Humax-Cd20 Fondazione Italiana Linfomi - ETS | Phase 3 | BB |
Sait101 Archigen Biotech Limited | Phase 3 | B |
Bendamustine Novartis Pharmaceuticals | Phase 3 | B |
Inotuzumab Ozogamicin Pfizer | Phase 3 | B |
Maraviroc National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | B |
View all 36 →
Same molecule, other indications
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →